BREAKWATER: First Line Encorafenib + Cetuximab +/- Chemotherapy in Patients Whose Tumors Express a BRAF V600E mutation
Condition: Colon or Rectal Adenocarcinoma
Sponsor: Pfizer
Full Title
Protocol C4221015: An Open-Label, Multicenter, Randomized Phase 3 Study of First-Line Encorafenib Plus Cetuximab With or Without Chemotherapy Versus Standard of Care Therapy With a Safety Lead-In of Encorafenib and Cetuximab Plus Chemotherapy in Participants With Metastatic BRAF V600E-Mutant Colorectal Cancer
Eligibility
Eligible patients will have a colon or rectal adenocarcinoma with a BRAF V600E mutation that is MSI-Stable, mismatch repair proficient, does not have a RAS mutation, and has not received therapy in the metastatic setting.
Contact
For more information you may contact the Research Department through the NYCBS HALO Messaging Center or call directly: 631-675-5075.
